ストックスクリーナーアプリを入手
77.35
0.34%
-0.26
プレマーケット:
77.66
0.31
+0.40%
前日終値:
$77.61
開ける：
$76.685
24時間の取引高:
1.42M
Relative Volume:
0.55
時価総額：
$11.39B
収益：
$4.39B
当期純損益:
$-1.58B
株価収益率:
-7.7661
EPS:
-9.96
ネットキャッシュフロー:
$546.00M
1週間 パフォーマンス:
+8.64%
1か月 パフォーマンス:
-11.63%
6か月 パフォーマンス:
-45.51%
1年 パフォーマンス:
-36.10%
1日の値動き範囲:
$75.62
$77.45
1週間の範囲:
$69.83
$79.37
52週間の値動き範囲:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
ILMN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
77.35 | 11.39B | 4.39B | -1.58B | 546.00M | -9.96 |
|
TMO
Thermo Fisher Scientific Inc
|
424.24 | 159.25B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.14 | 132.37B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
437.44 | 32.95B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
106.28 | 28.58B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.28 | 24.90B | 15.41B | 1.37B | 2.11B | 7.50 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-04 | 繰り返されました | Citigroup | Neutral |
| 2025-02-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-02-10 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-02-07 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-11-12 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-10-17 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-08-28 | アップグレード | Argus | Hold → Buy |
| 2024-08-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-08-14 | アップグレード | TD Cowen | Hold → Buy |
| 2024-07-10 | アップグレード | Citigroup | Neutral → Buy |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-01-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-12-11 | アップグレード | Citigroup | Sell → Neutral |
| 2023-11-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | 開始されました | Bernstein | Underperform |
| 2023-07-05 | 再開されました | JP Morgan | Neutral |
| 2023-01-25 | ダウングレード | Argus | Buy → Hold |
| 2023-01-05 | 開始されました | Scotiabank | Sector Perform |
| 2022-12-12 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-10-04 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Neutral |
| 2022-07-13 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-01-18 | アップグレード | Stifel | Hold → Buy |
| 2022-01-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-01-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-03-31 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | 開始されました | Barclays | Underweight |
| 2020-12-22 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-10-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-09-30 | 開始されました | Atlantic Equities | Overweight |
| 2020-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | ダウングレード | Stifel | Buy → Hold |
| 2020-09-22 | ダウングレード | UBS | Buy → Neutral |
| 2020-09-21 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-08-07 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-08-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-04-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | 開始されました | Wells Fargo | Underweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-10-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Illumina Inc (ILMN) 最新ニュース
Genetic Testing Market Generated Opportunities, Future Scope - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Next-Generation Sequencing (NGS) Data Analysis Market to Hit USD 4.21 Billion by 2032, Driven by Rising Genomic Research and Precision Medicine Initiatives – SNS Insider - GlobeNewswire Inc.
DNA and RNA Sample Preparation Market Projected To Witness - openPR.com
2024 Illumina Epigenetics Research Contest Winner Investigates Blood Transfusion Off-Target Effects - Illumina
Should You Hold Illumina (ILMN)? - MSN
June 6th Options Now Available For Illumina (ILMN) - Nasdaq
It’s all about accessibility: Developing technical training for the MiSeq i100 Series - Illumina
Veraxa makes a SPAC deal; Illumina discloses layoffs - Endpoints News
Resmed Taps Illumina Exec for Chief Investor Relations Officer Role - Medical Product Outsourcing
Microarray Market Projected To Witness Massive Growth, 2025-2032 | Thermo Fisher Scientific Inc.,Illumina Inc. - openPR.com
DNA Microarray Technology Market: Innovations & Opportunities - openPR.com
Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com
Genomic Cancer Testing Market Overall Study Report 2025-2032 | - openPR.com
Thomas Kean Jr purchases shares in Illumina and nVent Electric - Investing.com Australia
Resmed Names Salli Schwartz as Chief Investor Relations Officer - The Manila Times
Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns - Insider Monkey
Controlling Genes Market Detailed in New Research Report By 2032 - openPR.com
Illumina (ILMN) Receives a Buy from Leerink Partners - The Globe and Mail
Illumina, Tempus AI partner to drive genomic testing beyond cancer - MedTech Dive
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks - Yahoo Finance
DNA Methylation Market Deep Research Report with Forecast by 2032 | Illumina, Inc.,Thermo Fisher Scientific - openPR.com
RNA Sequencing Market Size, Share, Outlook, Industry Analysis, - openPR.com
MicroRNA Market Size, Share, Trends, Opportunities, - openPR.com
AI in Omics Studies Market Overall Study Report 2025-2032 | Thermo Fisher Scientific, Agilent Technologies, Illumina - openPR.com
Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation - Nasdaq
Illumina and Tempus join forces to expand genomic testing By Investing.com - Investing.com India
Illumina, Tempus AI Collaborating to Accelerate Clinical Use of Sequencing Tests - marketscreener.com
Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai Innovation - MarketScreener
Illumina and Tempus join forces to expand genomic testing - Investing.com
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation - PR Newswire
BofA Securities Cuts Price Target on Illumina to $75 From $90, Keeps Underperform Rating - MarketScreener
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Illumina (NASDAQ:ILMN) Price Target Cut to $112.00 by Analysts at Royal Bank of Canada - MarketBeat
Illumina : Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development - MarketScreener
Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent
Illumina To Announce First Quarter 2025 Financial Results On Thursday, May 8, 2025 - MarketScreener
Shareholders in Illumina (NASDAQ:ILMN) have lost 77%, as stock drops 6.8% this past week - simplywall.st
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025 - Yahoo Finance
Single-cell Omics Emerging Technologies and Markets Report 2025: 10x Genomics, Thermo Fisher & Illumina Lead $9.1 Billion Single-cell Omics Market by 2029 - Yahoo Finance
Cancer Profiling Market Positioned for Accelerated Growth with - openPR.com
Illumina (ILMN) Receives a Sell from Barclays - The Globe and Mail
Corvex’s Meister joins the board at Illumina. Here’s how he can create value for shareholders - MSN
Genotyping Assay Market Surges to USD 37.1 Billion by 2029: - openPR.com
Biotechnology company Illumina names Julie Hiner as comms head - Medical Marketing and Media
Illumina Inc (ILMN) 財務データ
収益
当期純利益
現金流量
EPS
0.12%
大文字化:
|
ボリューム (24 時間):